These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 22354528)

  • 21. [Efficacy and safety of pegylated-interferon plus ribavirin in HIV-infected patients co-infected with hepatitis C virus in clinical practice: a 32 cases observational follow-up].
    Seydi M; Morlat P; Bonnet F; Rambeloarisoa J; Bernard N; Lacoste D; Bonarek M; Trimoulet P; Ramanampamonjy R; Lafon ME; Dramé M; Beylot J
    Rev Med Interne; 2005 Apr; 26(4):280-7. PubMed ID: 15820563
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety of daclatasvir plus pegylated-interferon alfa 2a and ribavirin in previously untreated HCV subjects coinfected with HIV and HCV genotype-1: a Phase III, open-label study.
    Sulkowski MS; Fessel WJ; Lazzarin A; Berenguer J; Zakharova N; Cheinquer H; Côté P; Dieterich D; Gadano A; Matthews G; Molina JM; Moreno C; Pineda JA; Pulido F; Rivero A; Rockstroh J; Hernandez D; McPhee F; Eley T; Liu Z; Mendez P; Hughes E; Noviello S; Ackerman P
    Hepatol Int; 2017 Mar; 11(2):188-198. PubMed ID: 28210927
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Peginterferon alfa-2a plus ribavirin for HIV-HCV genotype 1 coinfected patients: a randomized international trial.
    Rodriguez-Torres M; Slim J; Bhatti L; Sterling R; Sulkowski M; Hassanein T; Serrão R; Sola R; Bertasso A; Passe And S; Stancic S
    HIV Clin Trials; 2012; 13(3):142-52. PubMed ID: 22592094
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Simeprevir for the treatment of hepatitis C and HIV/hepatitis C co-infection.
    Flanagan S; Crawford-Jones A; Orkin C
    Expert Rev Clin Pharmacol; 2014 Nov; 7(6):691-704. PubMed ID: 25209158
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of an induction period of pegylated interferon-α2a and ribavirin on early virological response in HIV-HCV-coinfected patients: results from the CORAL-2 study.
    Tural C; Solà R; Alvarez NP; Moltó J; Sánchez M; Zamora AM; Ornelas A; Laguno M; González J; von Wichmann MÁ; Téllez MJ; Paredes R; Clotet B;
    Antivir Ther; 2011; 16(6):833-41. PubMed ID: 21900715
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of Hepatitis C Virus (HCV) Eradication on Bone Mineral Density in Human Immunodeficiency Virus/HCV-Coinfected Patients.
    Carrero A; Berenguer J; Hontañón V; Guardiola JM; Navarro J; von Wichmann MA; Téllez MJ; Quereda C; Santos I; Sanz J; Galindo MJ; Hernández-Quero J; Jiménez-Sousa MA; Pérez-Latorre L; Bellón JM; Resino S; Esteban H; Martínez E; González-García J;
    Clin Infect Dis; 2021 Oct; 73(7):e2026-e2033. PubMed ID: 32930720
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Response to pegylated interferon plus ribavirin among HIV/hepatitis C virus-coinfected patients with compensated liver cirrhosis.
    Mira JA; García-Rey S; Rivero A; de los Santos-Gil I; López-Cortés LF; Girón-González JA; Téllez F; Márquez M; Merino D; Ríos-Villegas MJ; Macías J; Rivero-Juárez A; Pineda JA
    Clin Infect Dis; 2012 Dec; 55(12):1719-26. PubMed ID: 22955435
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Positive impact of hepatitis C virus (HCV) treatment on antiretroviral treatment adherence in human immunodeficiency virus-HCV coinfected patients: one more argument for expanded access to HCV treatment for injecting drug users.
    Roux P; Fugon L; Winnock M; Salmon-Céron D; Lacombe K; Sogni P; Spire B; Dabis F; Carrieri MP;
    Addiction; 2012 Jan; 107(1):152-9. PubMed ID: 21819472
    [TBL] [Abstract][Full Text] [Related]  

  • 29. HIV and HCV Therapies in 2016: Optimal Regimens.
    Sasadeusz J
    AIDS Rev; 2016; 18(4):212-221. PubMed ID: 27438581
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Advances in the management of HIV/HCV coinfection.
    Mandorfer M; Schwabl P; Steiner S; Reiberger T; Peck-Radosavljevic M
    Hepatol Int; 2016 May; 10(3):424-35. PubMed ID: 26758592
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Attitudes and potential barriers towards hepatitis C treatment in patients with and without HIV coinfection.
    Allyn PR; O'Malley SM; Ferguson J; Tseng CH; Chew KW; Bhattacharya D
    Int J STD AIDS; 2018 Mar; 29(4):334-340. PubMed ID: 28820346
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sustained virological response after ten days of triple anti-hepatitis C virus (HCV) therapy with telaprevir plus pegylated interferon and ribavirin in an HIV/HCV co-infected cirrhotic woman.
    Hasson H; Messina E; Merli M; Della Torre L; Morsica G; Bagaglio S; Lazzarin A; Uberti-Foppa C
    Int J Infect Dis; 2014 Dec; 29():100-2. PubMed ID: 25449243
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Coinfection with hepatitis C virus and HIV].
    Ruys TA; Reesink HW; Lange JM
    Ned Tijdschr Geneeskd; 2003 Oct; 147(42):2056-60. PubMed ID: 14606352
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ribavirin Concentrations Do Not Predict Sustained Virological Response in HIV/HCV-Coinfected Patients Treated with Ribavirin and Pegylated Interferon in the Swiss HIV Cohort Study.
    Kovari H; Russmann S; Ledergerber B; Müller D; Rotger M; Velli P; Cavassini M; Ambrosioni J; Bregenzer A; Stöckle M; Bernasconi E; Rauch A; Speck RF;
    PLoS One; 2015; 10(7):e0133879. PubMed ID: 26218843
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment of hepatitis C in HIV-coinfected patients.
    Hughes CA; Shafran SD
    Ann Pharmacother; 2006 Mar; 40(3):479-89; quiz 582-3. PubMed ID: 16507622
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of aging, glucose level, and HIV viral load on response to treatment with pegylated interferon plus ribavirin in HIV/HCV co-infected women.
    Nasta P; Maida I; Cattelan AM; Pontali E; Angeli E; Giralda M; Verucchi G; Caputo A; Iannacone C; Puoti M; Carosi G
    J Womens Health (Larchmt); 2015 Feb; 24(2):159-64. PubMed ID: 25682817
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hepatitis C direct-acting antiviral agents: changing the paradigm of hepatitis C treatment in HIV-infected patients.
    Martel-Laferrière V; Bichoupan K; Dieterich DT
    J Clin Gastroenterol; 2014 Feb; 48(2):106-12. PubMed ID: 24172182
    [TBL] [Abstract][Full Text] [Related]  

  • 38. High uptake of hepatitis C virus treatment in HIV/hepatitis C virus co-infected patients attending an integrated HIV/hepatitis C virus clinic.
    Kieran J; Dillon A; Farrell G; Jackson A; Norris S; Mulcahy F; Bergin C
    Int J STD AIDS; 2011 Oct; 22(10):571-6. PubMed ID: 21998177
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treating HCV in HIV 2013: on the cusp of change.
    Martel-Laferrière V; Dieterich DT
    Liver Int; 2014 Feb; 34 Suppl 1():53-9. PubMed ID: 24373079
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Therapeutical aspects and outcome of HIV/HCV coinfected patients treated with pegylated interferon plus ribavirin in an Italian cohort.
    Righi E; Beltrame A; Bassetti M; Lindstrom V; Mazzarello G; Dentone C; Di Biagio A; Ratto S; Viscoli C
    Infection; 2008 Aug; 36(4):358-61. PubMed ID: 18642111
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.